David Olmos, MD, PhD, discusses the evaluation of homologous recombination repair alterations in metastatic hormone-sensitive prostate cancer.
David Olmos, MD, PhD
Advertisement
David Olmos, MD, PhD, a medical oncologist, group leader, and distinguished investigator, Genetic, Genomics & Therapeutics in Prostate Cancer, at Instituto de Investigación Hospital 12 de Octubre in Madrid.
Articles by David Olmos, MD, PhD
David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5